Jeil Pharmaceutical Co Ltd (271980) - Cash Flow Conversion Efficiency

Latest as of June 2026: -0.037x

Based on the latest financial reports, Jeil Pharmaceutical Co Ltd (271980) has a cash flow conversion efficiency ratio of -0.037x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-9.47 Billion ≈ $-6.42 Million USD) by net assets (₩253.26 Billion ≈ $171.63 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Jeil Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Jeil Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how Jeil Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Jeil Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Jeil Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Jeil Pharmaceutical Co Ltd to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Rentokil Initial PLC LSE:RTO	0.077x
Burcelik Vana Sanayi ve Ticaret AS IS:BURVA	-2.892x
LOGISTRI FASTIGHETS AB F:6DV	N/A
Premier Technology Public Company Limited BK:PT	0.538x
SANTA ANA GLOBAL ENTERPRISES, S MC:STNA	N/A
Kluang Rubber Company Malaya KLSE:2453	-0.001x
Bundamedik Tbk PT JK:BMHS	0.083x
Wieson Technologies Co Ltd TWO:6272	0.046x

Annual Cash Flow Conversion Efficiency for Jeil Pharmaceutical Co Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of Jeil Pharmaceutical Co Ltd from 2017 to 2025. View today's stock price for Jeil Pharmaceutical Co Ltd for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩251.03 Billion ≈ $170.12 Million	₩-5.69 Billion ≈ $-3.86 Million	-0.023x	-254.72%
2024-12-31	₩219.32 Billion ≈ $148.63 Million	₩3.21 Billion ≈ $2.18 Million	0.015x	+146.19%
2023-12-31	₩157.03 Billion ≈ $106.42 Million	₩-4.98 Billion ≈ $-3.38 Million	-0.032x	+67.42%
2022-12-31	₩155.60 Billion ≈ $105.45 Million	₩-15.15 Billion ≈ $-10.26 Million	-0.097x	-185.29%
2021-12-31	₩167.35 Billion ≈ $113.41 Million	₩19.10 Billion ≈ $12.94 Million	0.114x	+203.36%
2020-12-31	₩172.48 Billion ≈ $116.89 Million	₩-19.05 Billion ≈ $-12.91 Million	-0.110x	-164.84%
2019-12-31	₩170.04 Billion ≈ $115.24 Million	₩28.96 Billion ≈ $19.62 Million	0.170x	+46.80%
2018-12-31	₩184.93 Billion ≈ $125.33 Million	₩21.45 Billion ≈ $14.54 Million	0.116x	+590.46%
2017-12-31	₩177.99 Billion ≈ $120.62 Million	₩-4.21 Billion ≈ $-2.85 Million	-0.024x	--

About Jeil Pharmaceutical Co Ltd

KO:271980 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$99.85 Million

₩147.34 Billion KRW

Market Cap Rank

#19295 Global

#951 in Korea

Share Price

₩10020.00

Change (1 day)

+0.10%

52-Week Range

₩9230.00 - ₩17390.00

All Time High

₩104611.38